Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 82.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 157,490 shares of the company’s stock after buying an additional 71,390 shares during the period. Renaissance Technologies LLC owned 0.35% of Cardiff Oncology worth $350,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after purchasing an additional 4,892 shares during the period. Thoroughbred Financial Services LLC acquired a new stake in Cardiff Oncology during the 2nd quarter worth $116,000. American Century Companies Inc. boosted its stake in Cardiff Oncology by 98.7% during the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock worth $101,000 after purchasing an additional 22,536 shares during the period. Ground Swell Capital LLC acquired a new stake in Cardiff Oncology during the 2nd quarter worth $38,000. Finally, Rhumbline Advisers acquired a new stake in Cardiff Oncology during the 2nd quarter worth $102,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

CRDF stock opened at $2.63 on Friday. Cardiff Oncology, Inc. has a one year low of $0.94 and a one year high of $6.42. The stock has a market capitalization of $122.43 million, a PE ratio of -2.89 and a beta of 1.96. The company has a fifty day moving average of $2.42 and a 200-day moving average of $3.08.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.12 million. Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. During the same quarter last year, the business posted ($0.25) EPS. Equities analysts forecast that Cardiff Oncology, Inc. will post -1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum assumed coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 price target for the company.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.